Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Hyperion Therapeutics, Inc. (HPTX - Snapshot Report) reported second-quarter 2013 loss of 27 cents per share, significantly narrower than the year-ago loss of $15.26 per share, but wider than the Zacks Consensus Estimate of a loss of 16 cents per share.

Quarter in Details

Quarterly revenues came in at $7.3 million. The company did not report revenues in the year-ago period. Reported revenues were higher than the Zacks Consensus Estimate of $2 million. The company has two marketed products, Ravicti and Buphenyl.

Research and development (R&D) expenses decreased 3.7% to $2.5 million. Hyperion is developing glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE). Hyperion completed a phase II study in HE which led to the decrease in R&D expenses due to reduced clinical development costs.

Selling, general, and administrative (SG&A) expenses increased sharply by 326% to $8.1 million.

The company expects operating expense between $41 million to $46 million for 2013 excluding stock based compensation and Buphenyl transaction related costs.

During the reported quarter, Hyperion acquired global rights to Buphenyl tablets and powder from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International, Inc. (VRX - Snapshot Report).

Buphenyl is approved by the U.S. Food and Drug Administration (FDA) to treat urea cycle disorders (UCD).Meanwhile, Ravicti was approved by the FDA in Feb 2013 as a nitrogen-binding agent for chronic management of adult and pediatric UCD patients more than two years of age who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. In May 2013, Ravicti qualified for orphan drug designation in the U.S. The company is planning to begin a phase III study in HE by the end of 2014.

Hyperion currently carries a Zacks Rank #3 (Hold). Companies that look well-positioned include Actelion Ltd. (ALIOF) and Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report), with a Zacks Rank #1 (Strong Buy) and a Zacks Rank #2 (Buy), respectively.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%